CLXT - Calyxt Switches Gears Again But The Cash Clock Keeps Ticking Down

• Calyxt is now on to its third business plan, pivoting from gene-edited seed traits to synthetic biology.
• The company is looking to produce molecules of interest to pharmaceutical, nutraceutical, and cosmeceutical companies through sustainable plant-based technology.
• The underlying science is sound enough, but management has to prove that they can do this at sustainable commercial levels and that they can attract meaningful commercial partners.
• Calyxt should have enough cash to complete proof-of-concept pilot-stage efforts, but the stock is speculative and very risky without meaningful commercial partnerships and funding.

For further details see: